Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
FDA approves Roche's oral breast cancer pill Wilserdly
00

FDA approves Roche's oral breast cancer pill Wilserdly

Nov 16, 2026

On November 16, 2026, the FDA approved Roche's oral breast cancer pill Wilserdly (giredestrant) for patients with advanced HR-positive, HER2-negative cancer exhibiting ESR1 gene mutations. Clinical trial data showed Wilserdly slowed tumor progression by a median of 4.5 months compared to standard therapy. The approval strengthens Roche's oncology footprint, with analysts projecting annual peak sales between $2.5 billion and $14.5 billion.

FDA approval details and trial results

  • ▪Wilserdly is approved for daily oral administration in combination with a targeted therapy for patients whose cancer progressed or recurred following prior therapy
  • ▪The FDA approved Wilserdly after the drug slowed median cancer progression by 4.5 months compared to an older treatment combination
  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer

Wilserdly dosing and safety warnings

  • ▪Wilserdly carries warning labels for bradycardia, a dangerously slow heart rate, and fetal toxicity in pregnant women
  • ▪Wilserdly is meant to be taken once daily until the disease worsens or the patient develops unacceptable toxic complications

Mechanism of action and ESR1 mutations

  • ▪Wilserdly, also known as giredestrant, is a selective estrogen receptor degrader designed to treat tumors driven by ESR1 gene mutations
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

Commercial outlook and market reaction

  • ▪Roche Holding AG's American depositary receipts increased by 1.2% in New York following the FDA approval of Wilserdly on November 16, 2026
  • ▪Roche Holding AG has stated that Wilserdly could become Roche's top-selling product ever
  • ▪Analysts forecast peak annual sales for Wilserdly ranging from $2.5 billion to $14.5 billion

Impact on Roche's oncology position

  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪Although Roche Holding AG historically established a major presence in breast cancer through Herceptin via Genentech, it had fallen behind rival pharmaceutical firms in oncology in recent years

3 sources

Reuters
US FDA approves Roche's oral treatment for advanced breast cancer | Reuters
View source article
STAT News
FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
View source article
Bloomberg
Roche Wins FDA Approval for Wilserdly Breast Cancer Pill in US
View source article

Story comments

Loading comments…

Related entities

United StatesSwitzerlandNew York

Related Projects

Genentech

Topics

Cancer & OncologyCancer and Cancer TreatmentDrug safetyTargeted cancer therapyCancer treatmentDrug Policy, Pricing & ApprovalClinical trialsPharmaceutical IndustryFDA drug approval